Promising cancer drug trial halted early – only 5 patients enrolled
NCT ID NCT06198426
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopped so early, we have very little information about how well the drug works or what risks it may carry.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3004 (an experimental drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors.
What could go wrong
This trial was terminated early with only 5 participants, so results are very limited. The drug is still in early testing and may not prove safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiang Su Province Hospital
Nanjing, Jiangsu, 210024, China
-
Liverpool Hospital
Sydney, New South Wales, 2170, Australia
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2770, Australia
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
Westmead Hospital
Sydney, New South Wales, 2170, Australia